Nir Peled
Universidad de Las Palmas de Gran Canaria
2 papers in the Anchorcite directory, published between 2016 and 2018, cited 17,030 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
Frequent co-authors
- Delvys Rodríguez‐Abreu · 2 papers
- Rina Hui · 2 papers
- Martin Reck · 1 paper
- Andrew George Robinson · 1 paper
- Tibor Csőszi · 1 paper
- Andrea Fülöp · 1 paper
- Maya Gottfried · 1 paper
- Ali Tafreshi · 1 paper
Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
Metadata from OpenAlex (CC0).